Recombinant Canine IL-8/CXCL8 Protein Summary
Details of Functionality |
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR2. The ED50 for this effect is 0.15-0.75 ng/mL. |
Source |
E. coli-derived canine IL-8/CXCL8 protein Ala23-Pro101 & Val28-Pro101 |
Accession # |
|
N-terminal Sequence |
Ala23 & Val28
|
Protein/Peptide Type |
Recombinant Proteins |
Gene |
CXCL8 |
Purity |
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Endotoxin Note |
<0.01 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
|
Theoretical MW |
9 kDa (mature), 8.5 kDa (N-terminal truncation). Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Purity |
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Reconstitution Instructions |
Reconstitute at 25 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Canine IL-8/CXCL8 Protein
Background
Interleukin-8 (IL-8), also known as CXCL8, GCP-1, and NAP-1, is a widely expressed proinflammatory member of the CXC family of chemokines. Near its N-terminus, this 8-9 kDa chemokine contains an ELR motif which is important for its angiogenic properties (1). CXCL8 can associate into a homodimer or a heterodimer with CXCL4/PF4 (2), and it can also interact with matrix and cell surface glycosaminoglycans (3). Mature canine CXCL8 shares 87%, 69%, and 82% amino acid (aa) sequence identiity with feline, human, and porcine CXCL8 (4). There is no CXCL8 gene counterpart in rodent. N-terminal truncation of CXCL8 by multiple proteases generates a range of shorter forms (5). The bioactivity of CXCL8 is regulated by these truncations, by CXCL8 citrullination at Arg5 (N-terminal to the ELR motif) (6), and by the decoy receptor DARC (7). CXCL8 effects are mediated through CXCR1/IL-8 RA, which is also used by CXCL6, and through CXCR2/IL-8 RB, which is used by multiple CXC chemokines (1). These receptors associate into functional homodimers and heterodimers with each other (8). Through both CXCR1 and CXCR2, CXCL8 promotes neutrophil adhesion to the vascular endothelium and migration to sites of inflammation (9). It triggers the antimicrobial activation of neutrophils through CXCR1 (10). CXCL8 also binds to Serpin A1/alpha-1 Antitrypsin, and this prevents CXCL8 interaction with CXCR1 (11). CXCL8 is upregulated in atherosclerotic lesions and other cardiac pathologies where it exacerbates inflammatory tissue damage (12). In addition, it induces VEGF expression, vascular endothelial cell proliferation, angiogenesis, and tumor cell invasiveness (13-16).
- Lazennec, G. and A. Richmond (2010) Trends Mol. Med. 16:133.
- Nesmelova, I.V. et al. (2005) J. Biol. Chem. 280:4948.
- Pichert, A. et al. (2012) Biomatter 2:142.
- Ishikawa, J. et al. (1993) Gene 131:305.
- Mortier, A. et al. (2008) Pharmacol. Ther. 120:197.
- Proost, P. et al. (2008) J. Exp. Med. 205:2085.
- Neote, K. et al. (1994) Blood 84:44.
- Munoz, L.M. et al. (2009) J. Immunol. 183:7337.
- Gerszten, R.E. et al. (1999) Nature 398:718.
- Jones, S.A. et al. (1996) Proc. Natl. Acad. Sci. USA 93:6682.
- Bergin, D.A. et al. (2010) J. Clin. Invest. 120:4236.
- Apostolakis, S. et al. (2009) Cardiovasc. Res. 84:353.
- Martin, D. et al. (2009) J. Biol. Chem. 284:6038.
- Li, A. et al. (2005) Angiogenesis 8:63.
- Waugh, D.J. and C. Wilson (2008) Clin. Cancer Res. 14:6735.
- Fernando, R.I. et al. (2011) Cancer Res. 71:5296.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Mu
Applications: ELISA
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
Species: Hu
Applications: BA
Species: Hu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: IHC, KO, WB
Species: Hu
Applications: ELISA
Species: Mu
Applications: ELISA
Species: Bv, Hu, Ma, Mu, Po, Rt
Applications: B/N, ChIP, CyTOF-ready, DB, Dual ISH-IHC, ELISA(Cap), ELISA, Flow-CS, Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, In vitro, KD, KO, PAGE, WB
Species: Hu
Applications: ICC, Simple Western, WB
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Hu
Applications: ELISA
Species: Ca, Hu, Mu, Rb, Rt
Applications: B/N, DB, ELISA, Flow-CS, Flow, Func, ICC/IF, IP, In vitro, WB
Species: Hu
Applications: BA
Publications for CXCL8/IL-8 (1608-CL) (0)
There are no publications for CXCL8/IL-8 (1608-CL).
By submitting your publication information earn gift cards and discounts for future purchases.
Reviews for CXCL8/IL-8 (1608-CL) (0)
There are no reviews for CXCL8/IL-8 (1608-CL).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
- Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
- Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for CXCL8/IL-8 (1608-CL) (0)